CN114747770A - Application of lactobacillus acidophilus in preparing food or medicine for preventing or treating antibiotic associated diarrhea - Google Patents
Application of lactobacillus acidophilus in preparing food or medicine for preventing or treating antibiotic associated diarrhea Download PDFInfo
- Publication number
- CN114747770A CN114747770A CN202210349140.4A CN202210349140A CN114747770A CN 114747770 A CN114747770 A CN 114747770A CN 202210349140 A CN202210349140 A CN 202210349140A CN 114747770 A CN114747770 A CN 114747770A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus acidophilus
- antibiotic
- associated diarrhea
- food
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 71
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 71
- 229940039695 lactobacillus acidophilus Drugs 0.000 title claims abstract description 71
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 66
- 235000013305 food Nutrition 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000004321 preservation Methods 0.000 claims abstract description 18
- 238000009629 microbiological culture Methods 0.000 claims abstract description 6
- 230000000968 intestinal effect Effects 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 21
- 235000013361 beverage Nutrition 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 229920001202 Inulin Polymers 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 52
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- 230000009266 disease activity Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 108010059881 Lactase Proteins 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 13
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 12
- 229960003180 glutathione Drugs 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 229940118019 malondialdehyde Drugs 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102100026189 Beta-galactosidase Human genes 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 229940116108 lactase Drugs 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 241000606124 Bacteroides fragilis Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910052564 epsomite Inorganic materials 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000017119 detection of oxidative stress Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to an application of lactobacillus acidophilus in preparing food or medicines for preventing or treating antibiotic-associated diarrhea; the lactobacillus acidophilus is named lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain, the preservation unit is the China general microbiological culture Collection center, the preservation time is 2020 years, 7 months and 20 days, the preservation number is CGMCC 1.12735, and the address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, Beicheng.
Description
Technical Field
The invention belongs to the technical field of microorganisms, relates to a new medicinal application of lactobacillus acidophilus, and particularly relates to an application of lactobacillus acidophilus in preparing food or medicines for preventing or treating antibiotic-associated diarrhea.
Background
The intestinal microorganisms play an important role in human body physiological metabolism and disease prevention, and a large amount of symbiotic bacteria inhabit and breed in the gastrointestinal tract and have a vital influence on maintaining the optimal host physiological and biochemical metabolic processes. The microbiota protects the host from infection by either directly defending against invading microorganisms or by coordinating the appropriate immune response. The composition and metabolic activity of human intestinal microorganisms is regulated by several external factors including diet and antibiotic therapy, which in turn affect the structure and health of host intestinal microorganisms.
Antibiotic Associated Diarrhea (AAD) has become a serious public health problem. AAD is a disorder of intestinal flora, caused by overuse of antibiotics, which kills antibiotic-sensitive strains while allowing drug-resistant strains to both survive and multiply. Possible pathogenic characteristics of AAD have been reported to include interference with bacterial metabolism and disruption of intestinal microflora balance.
Lactic acid bacteria are one of the probiotics, are one of the essential flora in human body, and are widely present in human intestinal tracts. The adhesiveness of lactic acid bacteria is beneficial to maintaining the structure of intestinal flora and better protecting the integrity of intestinal mucosa morphology and metabolic function. The good effect of lactic acid bacteria in the prevention and treatment of disturbances of the intestinal flora is mainly achieved by steric hindrance. Meanwhile, the probiotic lactic acid bacteria can generate more bacteriostatic components in the intestinal tract, such as acidic substances, antibacterial peptides, biological enzymes and the like, so that the activity of pathogenic bacteria can be inhibited. Since lactic acid bacteria have advantages of safety, health, no side effects, being able to be planted in animals as probiotics and exerting a variety of beneficial health, etc., lactic acid bacteria microecologics have been widely used as clinical supplements.
Intestinal lactase is mainly produced by microorganisms such as lactobacillus, large intestine rod bacteria, bacillus, bifidobacterium, enteroaerogen and streptococcus thermophilus, although it is also produced by intestinal mucosa and plays a key role in regulating intestinal functions. Low activity and lack of lactase can induce diarrhea; in this case, if lactase is provided, the symptoms can be improved. For the symptoms of intestinal dysbacteriosis caused by antibiotics, no clear treatment scheme is available, and corresponding medicines are mostly used for relieving or alleviating the symptoms of the related symptoms such as diarrhea and the like. While drug therapy for single symptoms has a high recurrence rate and a risk of causing more severe intestinal imbalance. The probiotic supplement is developed, can improve the structure of intestinal flora, has the antioxidation effect of eliminating free radicals harmful to human bodies and the like, is a very healthy treatment scheme, and has wide market application prospect.
CN106399141A discloses a bacteroides fragilis and its application, specifically relates to bacteroides fragilis ZY-312 with the collection number of CGMCC No.10685, and the application of the bacteroides fragilis in the preparation of drugs, pharmaceutical compositions, foods, health products and food additives for preventing and/or treating antibiotic-associated diarrhea, the bacteroides fragilis ZY-312 does not contain enterotoxin gene bft, compared with the existing bacteroides fragilis, has significantly higher bile salt and gastric acid tolerance, and can effectively prevent and/or treat antibiotic-associated diarrhea.
However, the prior art probiotic products for preventing or treating antibiotic-associated diarrhea are still very limited, and therefore it is very important to develop more probiotic products for improving antibiotic-associated diarrhea.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a new medicinal application of lactobacillus acidophilus, in particular to an application of lactobacillus acidophilus in preparing food or medicines for preventing or treating antibiotic-associated diarrhea.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides the use of lactobacillus acidophilus for the preparation of a food or a pharmaceutical product for the prevention or treatment of antibiotic-associated diarrhea;
the Lactobacillus acidophilus is named Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain, the preservation unit is the China general microbiological culture Collection center, the preservation time is 2020 years, 7 months and 20 days, the preservation number is CGMCC 1.12735, and the address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
The invention creatively discovers that the Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain has the effect of preventing, relieving or treating the antibiotic-associated diarrhea, namely creatively develops a novel strategy for preventing, relieving or treating the antibiotic-associated diarrhea. Lactobacillus acidophilus is one of the probiotics, is relatively healthy for human bodies, and is not easy to cause adverse reactions. Research shows that the product with the LA85 strain as the main effective component can obviously relieve antibiotic-associated diarrhea and obviously improve the pathological changes of the antibiotic-associated diarrhea, which is specifically shown in the following steps: (1) the weight of the mice with antibiotic-associated diarrhea is obviously increased; (2) the disease activity index of the antibiotic-associated diarrhea mouse is obviously reduced; (3) increasing the diversity of intestinal lactase of ADD mice; (4) the SOD and GSH levels of the ADD mice are obviously improved, and the MDA level is reduced; (5) reducing proinflammatory cell inflammatory factors in serum of mice with antibiotic-associated diarrhea: TNF-alpha, IL-1b and IL-6 levels. Therefore, the application of the compound in preparing the food or the medicine for preventing and/or treating the antibiotic-associated diarrhea or the antibiotic-associated diarrhea has good prospect.
Preferably, in the food or pharmaceutical product, the viable count of Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain is not less than 1 × 109CFU/mL or 1X 109CFU/g, e.g. 1X 109CFU/mL(CFU/g)、2×109CFU/mL(CFU/g)、3×109CFU/mL(CFU/g)、5×109CFU/mL(CFU/g)、7×109CFU/mL(CFU/g)、8×109CFU/mL(CFU/g)、1×1010CFU/mL(CFU/g)、5×1010CFU/mL(CFU/g)、1×1011CFU/mL (CFU/g), etc., and other specific point values within the range can be selected, which are not described in detail herein.
Preferably, in the food or pharmaceutical product, the Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain is present in the form of a lyophilized powder.
Preferably, the freeze-dried powder is prepared by a preparation method comprising the following steps:
inoculating the LA85 strain into a culture medium for culturing to obtain a culture solution; centrifuging the culture solution to obtain thalli; mixing the thallus with a freeze-drying protective agent, and freeze-drying to obtain the microbial agent.
Preferably, the culture medium comprises MRS medium.
Preferably, the MRS medium comprises, in concentrations: 8-12g/L of peptone, 8-12g/L of beef extract, 15-25g/L of glucose, 1-3g/L of sodium acetate, 3-7g/L of yeast powder and 1-3g/L, K of diammonium hydrogen citrate2PO4·3H2O 2-3g/L、MgSO4·7H2O 0.05-0.2g/L、MnSO40.01-0.1g/L, tween 800.5-2mL/L and cysteine hydrochloride 0.1-1 g/L.
Preferably, the inoculation amount of the LA85 strain is 1-5%, such as 1%, 2%, 2.5%, 3%, 3.5%, 4%, 5%, etc., and other specific values within the numerical range can be selected, which are not described in detail herein.
Preferably, the culturing is carried out for 12-48h (e.g. 12h, 14h, 15h, 17h, 18h, 20h, 22h, 24h, 36h, 48h, etc.) at 35-40 ℃ (e.g. 36 ℃, 36.5 ℃, 37 ℃, 37.5 ℃, 38 ℃, etc.), and other specific values in the above numerical range can be selected, which is not described in detail herein.
Preferably, the lyoprotectant comprises any one of or a combination of at least two of trehalose, lactose, and skim milk powder.
Preferably, the lyophilization is by a vacuum freezing method.
In a second aspect, the present invention provides the use of a lactobacillus acidophilus strain for the preparation of a food or a pharmaceutical product for increasing the diversity of intestinal laccases;
the Lactobacillus acidophilus is named as Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain, the preservation unit is China general microbiological culture Collection center, the preservation time is 2020, 7 and 20 days, the preservation number is CGMCC 1.12735, and the address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
The lactobacillus acidophilus is not aimed at non-diagnosis and/or treatment of diseases when used for preparing food for improving intestinal lactobacillus diversity.
In a third aspect, the present invention provides a medicament or food for the prevention or treatment of antibiotic-associated diarrhea, said medicament or food for the prevention or treatment of antibiotic-associated diarrhea comprising lactobacillus acidophilus according to the first aspect.
Preferably, the dosage form of the medicament comprises any one of suspension, granules, capsules, powder, tablets, emulsions, solutions, dripping pills, injections, suppositories, enemas, aerosols, patches or drops.
Preferably, the medicament or food further comprises any one of a filler, a wetting agent, a disintegrating agent, a binding agent, a protective agent, a prebiotic or a combination of at least two of them.
In a fourth aspect, the present invention provides a solid beverage having efficacy of alleviating antibiotic-associated diarrhea, the solid beverage comprising lactobacillus acidophilus according to the first aspect and inulin.
The inulin is creatively found to promote the lactobacillus acidophilus LA85 to exert the effect of preventing or treating the antibiotic-associated diarrhea, and a product obtained by combining the two types of inulin has more excellent effect of relieving the antibiotic-associated diarrhea.
In a fifth aspect, the present invention provides a method for preventing or treating symptoms of antibiotic-associated diarrhea, the method comprising: administering to the patient a therapeutic dose of the medicament of the third aspect.
In a sixth aspect, the present invention provides the use of Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain for the preparation of a product for reducing the levels of serum inflammatory factors TNF-alpha, IL-6 or IL-1b for the purpose of non-diagnosis and/or treatment of diseases.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively discovers that the Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain has the effect of preventing, relieving or treating the antibiotic-associated diarrhea, namely creatively develops a novel strategy for preventing, relieving or treating the antibiotic-associated diarrhea. Lactobacillus acidophilus is one of the probiotics, is relatively healthy for human bodies, and is not easy to cause adverse reactions. Research shows that the product with the LA85 strain as the main effective component can obviously relieve antibiotic-associated diarrhea and obviously improve the pathological changes of the antibiotic-associated diarrhea, which is specifically shown in the following steps: (1) the weight of the mice with antibiotic-associated diarrhea is obviously increased; (2) the disease activity index of the antibiotic-associated diarrhea mouse is obviously reduced; (3) increasing the diversity of intestinal lactase of ADD mice; (4) the SOD and GSH levels of the ADD mice are obviously improved, and the MDA level is reduced; (5) reducing proinflammatory cytokine in serum of mice with antibiotic-associated diarrhea: TNF-alpha, IL-1b and IL-6 levels. Therefore, the application of the compound in preparing the food or the medicine for preventing and/or treating the antibiotic-associated diarrhea or the antibiotic-associated diarrhea has good prospect.
Drawings
FIG. 1 is a graph showing the body mass of mice in CTL group, AAD group and LA85 group;
FIG. 2 is a graph of statistics of disease Activity index scores for CTL, AAD, LA85 groups of mice;
FIG. 3 is a graph showing statistical results of intestinal lactase diversity index (Chao1 index (A), ACE index (B) and Shannon index (C)) for mice in CTL group, AAD group and LA85 group;
FIG. 4 is a statistical chart showing the results of measuring the levels of superoxide dismutase (SOD) (A), Glutathione (GSH) (B) and Malondialdehyde (MDA) (C) in colon tissues of mice in CTL group, AAD group and LA85 group;
FIG. 5 is a graph showing the expression levels of TNF-. alpha.A, IL-1B (B) and IL-6 (C) in colon tissues of mice in CTL group, AAD group and LA85 group.
In each of the figures, the symbol "indicates p <0.05, the symbol" indicates p <0.01, and the symbol "indicates p < 0.001.
Detailed Description
The technical solution of the present invention is further described below by way of specific embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitation of the present invention.
The formulation of MRS medium referred to in the following examples is as follows:
MRS medium (g/L): 10g/L of peptone, 10g/L of beef extract, 20g/L of glucose, 2g/L of sodium acetate, 5g/L of yeast powder and 2g/L, K of diammonium hydrogen citrate2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO40.05g/L, Tween 801 mL/L and cysteine hydrochloride 0.5 g/L. Wherein the peptone, beef extract, glucose, sodium acetate, yeast powder, diammonium hydrogen citrate, and K2PO4·3H2O、MgSO4·7H2O、MnSO4Tween 80 and cysteine hydrochloride were purchased from the national pharmaceutical group chemicals ltd.
The test animals are SPF male C57BL/6 mice of 4 weeks old, and the mouse feed is purchased from Shanghai Slek company; ELISA kits purchased from Shanghai enzyme-linked biosciences, Inc. are used for measuring the levels of TNF-alpha, IL-1b and IL-6; for measuring the levels of superoxide dismutase (SOD), Glutathione (GSH) and Malondialdehyde (MDA), a detection kit purchased from Nanjing to build bioengineering company is used.
The Lactobacillus acidophilus related in the following embodiments is named as Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain, the preservation unit is China general microbiological culture Collection center, the preservation time is 2020, 7 and 20 days, the preservation number is CGMCC 1.12735, and the addresses are as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
The resistant dextrins referred to in the examples below are Fibersol-2 from food trade, Inc. of Nordson, Shanghai; the fructo-oligosaccharide is a 95 type product purchased from Yongzhao bio-products GmbH.
Example 1
The embodiment provides lactobacillus acidophilus LA85 freeze-dried powder, which is prepared by the following steps:
inoculating lactobacillus acidophilus LA85 strain into a culture medium according to the inoculation amount accounting for 3% of the total mass of the MRS culture medium, and culturing at 37 ℃ for 18h to obtain a culture solution; centrifuging the culture solution to obtain thalli; re-suspending thallus with trehalose lyophilized protectant (containing trehalose 100g/L, skimmed milk powder 100g/L, and water as solvent) at a mass ratio of 2:1 to obtain re-suspension; and (3) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain lactobacillus acidophilus LA85 freeze-dried powder, and detecting that the viable count of the lactobacillus acidophilus LA85 freeze-dried powder is 3000 hundred million CFU/g.
Test example 1
The test example explores the influence of lactobacillus acidophilus strain LA85 on the body weight, disease activity index, intestinal lactase diversity, oxidative stress marker content and serum proinflammatory cytokines of antibiotic-associated diarrhea mice:
(1) animal grouping and establishing antibiotic-associated diarrhea mouse model method:
the C57BL/6 mice were randomly divided into 3 groups of 10 mice, each of which was a normal control group (CTL group), an AAD model group (AAD group) and Lactobacillus acidophilus LA85 group (LA85 group). All mice were pathogen free. The mice are independently raised in cages, the environment is clean and quiet, the temperature is 23-25 ℃, and the humidity is 50-70%.
The experiment was carried out for a total of 7 days, a diarrhea model was made starting on day 1, and both AAD and LA85 mice were gavaged with a mixture of 0.1mL of 62.5g/L (40000U/mL) of cefradine and 0.1mL of 62.5g/L (40000U/mL) of gentamicin sulfate, while CTL mice were gavaged with 0.2mL of distilled water. All mice were gavaged 2 times daily for 5 consecutive days. After the AAD is successfully established, the mice in the AAD group have the symptoms of watery stool, erect hair, reduced food intake, reduced activity and the like.
(2) And (3) intervention: the Lactobacillus acidophilus LA85 lyophilized powder solution prepared in example 1 was orally administered to mice in LA85 group 2h before the start of molding on the first day of the experiment (each mouse was gavaged with 1X 10 of the powder per day)9CFU, once daily until the end of the experiment), while the CTL group and the AAD group were given the same volume of physiological saline.
(3) Effect on body weight of antibiotic-associated diarrheal mice:
all mice were evaluated for body weight daily from day one to day seven of molding, and a volume mass curve was plotted according to the change in body mass of each group of mice, as shown in fig. 1. As can be seen from fig. 1, the reduction in body mass of mice after treatment with LA85 was significantly improved compared to AAD. At the same time, it was observed that: normal control group (CTL group) mice were active, fed normally, and had no diarrhea; AAD model group (AAD group) mice had little activity with macroscopic diarrhea; the mice of the lactobacillus acidophilus LA85 group (LA85 group) suffered relatively mild diarrhea compared to the AAD group.
(4) Disease activity index scoring for antibiotic-associated diarrhea mice:
disease activity index scoring, an important indicator for assessment of colonic damage, was performed on each group of mice on day 7 of the experiment, and the disease activity index scoring criteria are given in the following table:
| weight loss | Hardness of feces | Score of |
| Without change | Is normal | 0 |
| 1–5％ | |
1 |
| 5–10％ | |
2 |
| 10–20％ | Diarrhea (diarrhea) | 3 |
| ≥20％ | Diarrhea (diarrhea) | 4 |
The results are shown in FIG. 2: the disease activity index score was significantly reduced in mice of the LA85 group compared to the AAD group (p < 0.001).
(5) Intestinal lactase analysis of antibiotic-associated diarrheal mice:
groups of mice were fecal harvested on day 7 of the experiment. The intestinal bacterial lactase gene was amplified using the forward primer (5 '-TRRGCAACGAATACGGSTG-3') and the reverse primer (5 '-ACCATGAARTTSGTGGTSARCGG-3'). The PCR amplification system (25. mu.L) contained 11.25. mu.L of sterile ultrapure water, 0.25. mu. L q5 high fidelity DNA polymerase, 5. mu.L of 5 × reaction buffer, 5. mu.L of 5 × high GC buffer, 0.5. mu.L of dNTPs (10mmol/L), 1. mu.L of template DNA, 1. mu.L of forward primer (10. mu. mol/L) and 1. mu.L of reverse primer (10. mu. mol/L). The PCR reaction conditions are as follows: the reaction is carried out at 98 ℃ for 30s, at 98 ℃ for 15s, at 46 ℃ for 30s, at 72 ℃ for 30s and at 72 ℃ for 5 min. PCR products were extracted from 1.5% agarose gels and purified using AxyPred gel extraction kit (Axygen, Scientific inc., Union City, Calif., United States). The purified product was sequenced using MiSeq. Sequencing results sequence analysis was performed using QIIME2 software. The diversity of lactase genes was analyzed using the operational taxonomic units for lactase genes (alpha diversity analysis).
The results are shown in FIG. 3: the diversity of the intestinal lactase genes of the mice in the AAD group was significantly reduced, as shown by the significant decrease in both the Chao1 index (a in fig. 3), the ACE index (B in fig. 3), and the Shannon index (C in fig. 3). After lactobacillus acidophilus dry prediction, the intestinal lactase gene abundance (Chao1 index and ACE index) and diversity (Shannon index) of mice in the LA85 group are obviously improved.
(6) Detection of oxidative stress markers:
mice were sacrificed on day 7 of the experiment and the colons of each group of mice were added to saline and then homogenized to give a 10% colons homogenate. The homogenate was centrifuged for 10min (5,000g, 4 ℃) to obtain a supernatant. The levels of superoxide dismutase (SOD), Glutathione (GSH) and Malondialdehyde (MDA) are measured by a detection kit of Nanjing BioEngineers.
The results are shown in FIG. 4: (wherein A is superoxide dismutase (SOD), B is Glutathione (GSH), and C is Malondialdehyde (MDA) level): the AAD group significantly reduced SOD and GSH levels (p <0.001) in mice with antibiotic-associated diarrhea compared to normal mice. After lactobacillus acidophilus LA85 was administered to mice with antibiotic-associated diarrhea, the levels of SOD and GSH were significantly increased. In addition, compared with a normal control group, the MDA content of the antibiotic-associated diarrhea model group is obviously increased (p is less than 0.001). In contrast, lactobacillus acidophilus LA85 significantly reduced MDA levels in mice with antibiotic-associated diarrhea (p < 0.001).
(7) The enzyme-linked immunosorbent assay (ELISA) detects the expression of serum tumor necrosis factor TNF-alpha, interleukin 1b (IL-1b) and interleukin 6(IL-6) of each group of mice:
the levels of inflammatory mediators (TNF-. alpha., IL-1b and IL-6) in serum were measured using an ELISA kit (Shanghai Min, Biotechnology Co., Ltd.) according to the kit instructions.
The results are shown in FIG. 5: compared with the CTL group, the serum TNF-alpha (A in figure 5), interleukin 1B (B in figure 5) and interleukin 6 (C in figure 5) of the mice in the AAD group are obviously increased, and the difference is statistically significant (p is less than 0.001). Compared with the AAD group, the level of serum TNF-alpha, interleukin 1b and interleukin 6 of mice in the lactobacillus acidophilus LA85 intervention group is reduced, and the difference has statistical significance (p is less than 0.001). In general, inflammatory cytokines play a role in the process of damage to the intestinal mucosal barrier, and the inflammatory response increases intercellular permeability, thereby disrupting the intestinal mucosal barrier and exacerbating intestinal inflammation. The lactobacillus acidophilus LA85 is used for prognosis, and can reduce the generation of proinflammatory cytokine serum TNF-alpha, interleukin 1b and interleukin 6. This indicates that lactobacillus acidophilus LA85 can inhibit inflammation and thus act to treat antibiotic-associated diarrhea.
Example 2
The embodiment provides a solid beverage with the effect of relieving antibiotic-associated diarrhea, and the preparation method comprises the following steps:
0.1g of the lactobacillus acidophilus freeze-dried powder prepared in the example 1 is mixed with 1.9g of inulin to be homogenized, and the number of the viable bacteria is detected to be 10 hundred million CFU/g.
Example 3
The embodiment provides a solid beverage with the effect of relieving antibiotic-associated diarrhea, and the preparation method of the solid beverage comprises the following steps:
0.1g of lactobacillus acidophilus freeze-dried powder prepared in the embodiment 1 is mixed and homogenized with 1.9g of resistant dextrin, and the number of the live bacteria is detected to be 10 hundred million CFU/g.
Example 4
The embodiment provides a solid beverage with the effect of relieving antibiotic-associated diarrhea, and the preparation method of the solid beverage comprises the following steps:
0.1g of lactobacillus acidophilus freeze-dried powder prepared in the embodiment 1 is mixed and homogenized with 1.9g of fructo-oligosaccharide, and the number of the live bacteria is detected to be 10 hundred million CFU/g.
Test example 2
This test example explores the effect of the solid beverages prepared in examples 2-4 on the disease activity index of mice with antibiotic-associated diarrhea:
(1) animal grouping and establishing antibiotic-associated diarrhea mouse model method:
the C57BL/6 mice were randomly divided into 6 groups of 10 mice each, which were a normal control group (CTL group), an AAD model group (AAD group), a lactobacillus acidophilus LA85 group (LA85 group), and a solid drink group (solid drink a group as product of example 2, solid drink B group as product of example 3, and solid drink C group as product of example 4).
The molding method was the same as in test example 1.
(2) And (3) intervention: the Lactobacillus acidophilus LA85 lyophilized powder solution prepared in example 1 was orally administered to mice of LA85 group 2h before molding on test day 1 (each mouse was gavaged with 1X 10 per day)9CFU once a day until the end of the experiment), solid beverage groups mice orally administered the solid beverage solution prepared in examples 2-4 (each mouse was gavaged 1 × 10 a day)9CFU, once daily until the end of the experiment), while the CTL group and the AAD group were given the same volume of physiological saline.
(3) Disease activity index scoring for antibiotic-associated diarrhea mice:
the disease activity index scores, which are important indicators for assessing colonic damage, were scored on each group of mice on day 7 of the experiment using the disease activity index scoring criteria given in the following table:
the results are shown in table 1:
TABLE 1
| Group of | Index of disease |
| CTL group | |
| 0 | |
| AAD group | 3.6±0.4 |
| LA85 group | 2.2±0.32 |
| Solid beverage group A | 1.6±0.21 |
| Solid beverage B group | 2.1±0.14 |
| Solid beverage group C | 2.2±0.42 |
As can be seen from the data in Table 1: compared with the AAD group, the disease activity index scores of mice in the LA85 group and the solid beverage group were significantly reduced (p <0.001), and compared with the LA85 group, the disease activity index score of the solid beverage group a was lower (p <0.001), and the effect of alleviating antibiotic-associated diarrhea was better.
The applicant states that the invention is illustrated by the above examples of the use of a lactobacillus acidophilus strain according to the invention for the preparation of a food or pharmaceutical product for the prevention or treatment of antibiotic-associated diarrhea, but the invention is not limited to the above examples, that is to say it does not mean that the invention must be carried out in reliance thereon. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. Use of Lactobacillus acidophilus for the preparation of a food or a pharmaceutical product for the prevention or treatment of antibiotic-associated diarrhea; the Lactobacillus acidophilus is named as Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain, the preservation unit is China general microbiological culture Collection center, the preservation time is 2020, 7 and 20 days, the preservation number is CGMCC 1.12735, and the address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, Beicheng.
2. The use according to claim 1, wherein the viable count of Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain in said food or pharmaceutical product is not less than 1 x 109CFU/mL or 1X 109CFU/g。
3. Use according to claim 1 or 2, wherein the Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain is present in the form of a lyophilized powder in the food or pharmaceutical product.
4. The use of claim 3, wherein the lyophilized powder is prepared by a method comprising the steps of:
inoculating the LA85 strain into a culture medium for culture to obtain a culture solution; centrifuging the culture solution to obtain thalli; mixing the thallus with a freeze-drying protective agent, and freeze-drying to obtain the microbial agent.
5. The use of claim 4, wherein the LA85 strain is inoculated in an amount of 1-5%;
preferably, the culturing is at 35-40 ℃ for 12-48 h.
6. The use of claim 4, wherein the lyoprotectant comprises any one or a combination of at least two of trehalose, lactose, skim milk powder;
preferably, the lyophilization is by a vacuum freezing method.
7. An application of Lactobacillus acidophilus in preparing food or medicine for improving intestinal lactobacillus diversity; the Lactobacillus acidophilus is named as Lactobacillus acidophilus (Lactobacillus acidophilus) LA85 strain, the preservation unit is China general microbiological culture Collection center, the preservation time is 2020, 7 and 20 days, the preservation number is CGMCC 1.12735, and the address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
8. A medicament or food for the prevention or treatment of antibiotic-associated diarrhea, characterized in that the medicament or food for the prevention or treatment of antibiotic-associated diarrhea comprises lactobacillus acidophilus according to claim 1.
9. The medicament or food for preventing or treating antibiotic-associated diarrhea according to claim 8, wherein the medicament or food further comprises any one of or a combination of at least two of a filler, a wetting agent, a disintegrant, a binder, a protective agent, and a prebiotic.
10. A solid beverage having efficacy of alleviating antibiotic-associated diarrhea, wherein the solid beverage comprises lactobacillus acidophilus according to claim 1 and inulin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210349140.4A CN114747770A (en) | 2022-04-01 | 2022-04-01 | Application of lactobacillus acidophilus in preparing food or medicine for preventing or treating antibiotic associated diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210349140.4A CN114747770A (en) | 2022-04-01 | 2022-04-01 | Application of lactobacillus acidophilus in preparing food or medicine for preventing or treating antibiotic associated diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114747770A true CN114747770A (en) | 2022-07-15 |
Family
ID=82329384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210349140.4A Pending CN114747770A (en) | 2022-04-01 | 2022-04-01 | Application of lactobacillus acidophilus in preparing food or medicine for preventing or treating antibiotic associated diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114747770A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080006231A (en) * | 2006-07-11 | 2008-01-16 | 한국생명공학연구원 | A novel strain of lactobacillus acidophilus la-12 produced lactase |
| CN101953916A (en) * | 2010-09-13 | 2011-01-26 | 杜丹 | Composition containing L. acidophilus 1.1878 and Chinese medicaments and application thereof |
| CN112057479A (en) * | 2020-11-16 | 2020-12-11 | 招远新兴化工有限公司 | Probiotic composition capable of relieving diarrhea caused by antibiotics |
| CN112251372A (en) * | 2020-10-10 | 2021-01-22 | 内蒙古普泽生物制品有限责任公司 | Lactobacillus acidophilus with galactosidase activity and lactose tolerance and application thereof |
| CN113368139A (en) * | 2021-07-02 | 2021-09-10 | 微康益生菌(苏州)股份有限公司 | Microbial compound with effect of relieving irritable bowel syndrome and preparation method and application thereof |
-
2022
- 2022-04-01 CN CN202210349140.4A patent/CN114747770A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080006231A (en) * | 2006-07-11 | 2008-01-16 | 한국생명공학연구원 | A novel strain of lactobacillus acidophilus la-12 produced lactase |
| CN101953916A (en) * | 2010-09-13 | 2011-01-26 | 杜丹 | Composition containing L. acidophilus 1.1878 and Chinese medicaments and application thereof |
| CN112251372A (en) * | 2020-10-10 | 2021-01-22 | 内蒙古普泽生物制品有限责任公司 | Lactobacillus acidophilus with galactosidase activity and lactose tolerance and application thereof |
| CN112057479A (en) * | 2020-11-16 | 2020-12-11 | 招远新兴化工有限公司 | Probiotic composition capable of relieving diarrhea caused by antibiotics |
| CN113368139A (en) * | 2021-07-02 | 2021-09-10 | 微康益生菌(苏州)股份有限公司 | Microbial compound with effect of relieving irritable bowel syndrome and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 罗学娅等: "嗜酸性乳杆菌培养上清液对抗生素相关性腹泻小鼠肠道菌群的影响", 《世界华人消化杂志》 * |
| 翁梁: "《益生菌》", 31 December 2019, 中国轻工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017020784A1 (en) | Bacteroides fragilis and application thereof | |
| Yan et al. | Bifidobacterium longum subsp. longum YS108R fermented milk alleviates DSS induced colitis via anti-inflammation, mucosal barrier maintenance and gut microbiota modulation | |
| CN108721337B (en) | Microbial agent for preventing tumor chemotherapy intestinal toxicity | |
| CN112914103A (en) | Probiotic composition for resisting helicobacter pylori infection and application thereof | |
| US11376289B2 (en) | Composition and uses thereof | |
| CN114259056A (en) | Application of Lactobacillus rhamnosus in preparing food or medicine for preventing and/or treating ulcerative colitis | |
| CN113832077A (en) | Lactobacillus rhamnosus and application thereof | |
| CN111548972A (en) | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN117106679B (en) | Probiotic agent for relieving insulin resistance and application thereof | |
| CN111575214A (en) | Bifidobacterium lactis with helicobacter pylori resisting function and application thereof | |
| CN113474447A (en) | Strains, compositions and methods of use | |
| CN114287633B (en) | Probiotic composition containing cranberry and application thereof in helicobacter pylori resistance | |
| CN116077536A (en) | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof | |
| CN117286077B (en) | Probiotics for preventing and treating acute radioactive intestinal injury and application thereof | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN111544456A (en) | Probiotic formula and application thereof | |
| CN114747770A (en) | Application of lactobacillus acidophilus in preparing food or medicine for preventing or treating antibiotic associated diarrhea | |
| WO2022134658A1 (en) | Bifidobacterium breve strain capable of preventing and alleviating psoriasis, and application thereof | |
| CN117070426B (en) | Probiotic agent for improving alcoholic fatty liver disease and application thereof | |
| CN117384790B (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of sleep-aiding drugs | |
| CN113939281A (en) | Microbial compositions and methods for increasing tolerance and extending shelf life | |
| CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof | |
| CN116574634B (en) | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug | |
| Bhattacharyya | Emergence of probiotics in therapeutic applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220715 |